Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to Analysts

Key Points

• Analysts remain bullish on Ascendis Pharma: Twenty analysts give the stock a consensus “Buy” rating, with an average 12-month price target of $309.26 versus a recent price of $234.33.
• Recent analyst targets range from $287 to $330, while the company’s latest quarter exceeded revenue expectations but missed consensus EPS estimates, reporting $387.22 million in revenue and $1.03 EPS.
• Insider ownership stands at 40%: A senior vice president sold 3,000 shares, while director Jean-Jacques Bienaimé purchased 2,000 shares; institutional investors also increased several positions during the third quarter.

Shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) have been assigned a consensus recommendation of "Buy" from the twenty analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eighteen have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $309.26.

Several equities research analysts recently issued reports on the company. Jefferies Financial Group cut their price target on Ascendis Pharma A/S from $333.00 to $330.00 and set a "buy" rating for the company in a research note on Monday, August 31st. Cantor Fitzgerald restated an "overweight" rating and set a $300.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday, September 25th. BMO Capital Markets restated an "outperform" rating on shares of Ascendis Pharma A/S in a research note on Thursday, September 10th. Oppenheimer lifted their price objective on Ascendis Pharma A/S from $304.00 to $312.00 and gave the company an "outperform" rating in a report on Tuesday, September 1st. Finally, Raymond James Financial downgraded Ascendis Pharma A/S from a "strong-buy" rating to an "outperform" rating and set a $287.00 target price for the company. in a research report on Tuesday, September 15th.

Insiders Place Their Bets

In related news, SVP Mads Bodenhoff sold 3,000 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $270.19, for a total value of $810,570.00. Following the completion of the transaction, the senior vice president owned 3,000 shares of the company's stock, valued at $810,570. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jean-Jacques Bienaimé acquired 2,000 shares of the business's stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $246.33 per share, with a total value of $492,660.00. Following the transaction, the director directly owned 2,900 shares of the company's stock, valued at $714,357. This trade represents a 222.22% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 40.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 28,468.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,428 shares of the biotechnology company's stock worth $1,237,000 after acquiring an additional 5,409 shares in the last quarter. Diversify Advisory Services LLC increased its stake in Ascendis Pharma A/S by 10.0% in the third quarter. Diversify Advisory Services LLC now owns 12,299 shares of the biotechnology company's stock valued at $2,787,000 after acquiring an additional 1,118 shares during the last quarter. New Wave Wealth Advisors LLC raised its position in Ascendis Pharma A/S by 7.8% during the third quarter. New Wave Wealth Advisors LLC now owns 5,189 shares of the biotechnology company's stock valued at $1,158,000 after purchasing an additional 375 shares in the last quarter. IFP Advisors Inc raised its position in Ascendis Pharma A/S by 54.8% during the third quarter. IFP Advisors Inc now owns 667 shares of the biotechnology company's stock valued at $152,000 after purchasing an additional 236 shares in the last quarter. Finally, Burns Matteson Capital Management LLC acquired a new position in Ascendis Pharma A/S during the third quarter valued at approximately $560,000.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $234.33 on Wednesday. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $14.62 billion, a P/E ratio of 18.18 and a beta of 0.38. Ascendis Pharma A/S has a 12-month low of $188.07 and a 12-month high of $282.15. The firm has a 50-day moving average price of $243.53 and a two-hundred day moving average price of $242.62.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Analysts anticipate that Ascendis Pharma A/S will post 3.55 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases. The company uses its proprietary TransCon technology platform to design long-acting medicines intended to improve treatment convenience, maintain controlled drug exposure, and address unmet medical needs.

Its commercial products include SKYTROFA (lonape­gsomatropin-tcgd), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a once-daily therapy for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.